Medications That Commonly Worsen Pulmonary Fibrosis
Disease-modifying antirheumatic drugs (DMARDs), antineoplastic agents, and cardiovascular medications are the most common culprits that can worsen or induce pulmonary fibrosis, accounting for nearly 80% of drug-induced cases.
Primary Offending Drug Classes
Based on a comprehensive 23-year analysis of FDA adverse event reports, the following medications pose the highest risk 1:
1. DMARDs (39.4% of cases)
- Methotrexate - most frequently implicated
- Leflunomide
- Gold salts
- Penicillamine
- TNF antagonists (etanercept, infliximab) - can cause fulminant, sometimes fatal fibrosis even after drug withdrawal 2
2. Antineoplastic Agents (26.4% of cases)
- Bleomycin - classic offender via oxygen radical release and NF-κB activation 3
- Cyclophosphamide
- Mitomycin
- Tamoxifen - acts via TGF-β release 3
3. Cardiovascular Agents (12.6% of cases)
- Amiodarone - inhibits phospholipases leading to phospholipid accumulation and immune suppression 3
- Procainamide
4. Corticosteroids (4.6% of cases)
Paradoxically, while used to treat acute exacerbations 4, chronic use is associated with fibrosis progression.
5. Immunosuppressive Agents (4.0% of cases)
Less Common but Documented Offenders
Antibiotics:
- Nitrofurantoin - well-established association 3
Psychotropic Medications:
- Sertraline and risperidone - rare but can cause rapidly progressive fibrosis with eosinophilic infiltration 5
Critical Clinical Considerations
Exponentially Rising Trend
The incidence of drug-induced pulmonary fibrosis reports increased exponentially from 2000-2022 (R² = 0.88), with DMARDs and antineoplastic agents showing the steepest increases 1. This reflects both increased drug utilization and heightened awareness.
Mechanism-Based Risk Stratification
Drug-induced fibrosis operates through three primary pathways 3:
- Oxygen radical release (bleomycin, mitomycin) → TNF-α and IL-1β via NF-κB activation
- TGF-β pathway activation (tamoxifen)
- Phospholipase inhibition (amiodarone) → phospholipid accumulation and immune dysfunction
Common Pitfall: Autoimmune Disease Context
Be cautious when attributing fibrosis solely to medications in patients with rheumatoid arthritis, systemic lupus erythematosus, or other connective tissue diseases 3, as these conditions independently predispose to pulmonary fibrosis. The 29% incidence of progressive pulmonary fibrosis in CTD-ILD 6 makes distinguishing drug-induced from disease-related fibrosis challenging.
Monitoring Algorithm
For patients on high-risk medications, the ATS/ERS/JRS/ALAT guidelines recommend 4:
- Pulmonary function testing every 4-6 months (FVC decline >5% or DLCO decline >10% signals progression)
- Annual HRCT if clinical suspicion of worsening
- Immediate HRCT if acute exacerbation suspected
- Look for: increased traction bronchiectasis, new ground-glass opacity, new/increased honeycombing, increased reticular abnormalities
Management Approach
Immediate drug withdrawal is critical - this is the single most important intervention. Most cases respond to discontinuation plus corticosteroids 3, though rare cases (particularly with TNF antagonists) may progress to fatal fibrosis despite aggressive treatment 2.
Patient Demographics at Highest Risk
Mean age 66.5 years, slight male predominance (52.1%) 1 - adjust monitoring intensity accordingly in older patients on multiple high-risk agents.